Clerk of the House of Representatives
Legislative Resource Center
135 Cannon Building
Washington, DC 20515
http://lobbyingdisclosure.house.gov 		Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510
http://www.senate.gov/lobby
LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Organization/Lobbying Firm Self Employed Individual
Pharmaceutical Care Management Association

2. Address

Address1
325 7th Street NW, 9th Floor
 Address2
​
City
WASHINGTON
 State
DC
 Zip Code
20004
 Country
USA

3. Principal place of business (if different than line 2)

City
​
State
​
Zip Code
​
Country
​
4a. Contact Name b. Telephone Number c. E-mail
​Mr.
​Jonathan Heafitz
​2027565735
​jheafitz@pcmanet.org
5. Senate ID#
​31348-12
7. Client Name Self Check if client is a state or local government or instrumentality
​Pharmaceutical Care Management Association
6. House ID#
​340040000
TYPE OF REPORT 8. Year
​2024
 Q1 (1/1 - 3/31) Q2 (4/1 - 6/30) Q3 (7/1 - 9/30) Q4 (10/1 - 12/31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report Termination Date
​
11. No Lobbying Issue Activity
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13
12. Lobbying 13. Organizations
INCOME relating to lobbying activities for this reporting period was: EXPENSE relating to lobbying activities for this reporting period were:
Less than $5,000
Less than $5,000
$5,000 or more $
​
$5,000 or more $
​4,165,073.00
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.
Method A. Reporting amounts using LDA definitions only

Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature
Digitally Signed By: Jonathan Heafitz
 Date
10/21/2024 11:51:40 AM

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

Issues related to prescription drug coverage and pharmacy benefits

Regulatory and proposed legislative changes to Medicare Part D prescription drug benefits

S.652 - Safe Step Act
S.2973 - Modernizing and Ensuring PBM Accountability Act
S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act
H.R.2880 - Protecting Patients Against PBM Abuses Act
H.R.4881 - To amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program
H.R.5378 - Lower Costs More Transparency Act
H.R.5385 - Medicare PBM Accountability Act
H.R. 8261- Preserving Telehealth, Hospital, and Ambulance Access Act, Sec. 302
H.R.7623- Telehealth Modernization Act of 2024
H.R.4758- Accelerating Kids Access to Care Act AINS Sec. 3
H.R.9096- Pharmacists Fight Back Act

Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation


17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP)

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
JC
Scott
​
​
Jonathan
Heafitz
​
​
Jocelyn
Wiles
​
​
Lucia
Lebens
​
​
Emily
Threadgill
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

Issues related to prescription drug coverage and pharmacy benefits

Issues related to the prescription drug marketplace, patents, and competition

Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits

S.113 - Prescription Pricing for the People Act
S.127 - Pharmacy Benefit Manager Transparency Act
S.142 - Preserve Access to Affordable Generics and Biosimilars Act
S.148 - Stop STALLING Act
S.652 - Safe Step Act
S.775 - Increasing Transparency in Generic Drug Applications Act
S.1067 - Ensuring Timely Access to Generics Act
S.1114 - Expanding Access to Low-Cost Generics Act
S.1120 - Improved Access to Affordable Medications Act
S.1128 - Ensuring Access to Generic Medications Act
S.1339 - Pharmacy Benefit Manager Reform Act
S.1542/H.R.6283 - Delinking Revenue from Unfair Gouging (DRUG) Act
S.2973 - Modernizing and Ensuring PBM Accountability Act
S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act
S.150 - Affordable Prescriptions for Patients Act of 2023
H.R.1352 - Increasing Access to Biosimilars Act
H.R.1790 - Biologics Competition Act
H.R.2880 - Protecting Patients Against PBM Abuses Act
H.R.4881 - To amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program
H.R.5378 - Lower Costs More Transparency Act
H.R.5385 - Medicare PBM Accountability Act
H.R. 8261- Preserving Telehealth, Hospital, and Ambulance Access Act, Sec. 302
H.R.7623- Telehealth Modernization Act of 2024
H.R.4758- Accelerating Kids Access to Care Act AINS Sec. 3
H.R.9096- Pharmacists Fight Back Act

Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP)

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
JC
Scott
​
​
Jonathan
Heafitz
​
​
Jocelyn
Wiles
​
​
Lucia
Lebens
​
​
Emily
Threadgill
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks

Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, pharmacy networks, and mail-service pharmacy

S.113 - Prescription Pricing for the People Act
S.127 - Pharmacy Benefit Manager Transparency Act
S.1339 - Pharmacy Benefit Manager Reform Act
S.2973 - Modernizing and Ensuring PBM Accountability Act
S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act
H.R.2880 - Protecting Patients Against PBM Abuses Act
H.R.5378 - Lower Costs More Transparency Act
H.R.5385 - Medicare PBM Accountability Act
S.1542/H.R.6283 - Delinking Revenue from Unfair Gouging (DRUG) Act
H.R. 8261- Preserving Telehealth, Hospital, and Ambulance Access Act, Sec. 302
H.R.7623- Telehealth Modernization Act of 2024
H.R.4758 - Accelerating Kids Access to Care Act AINS Sec. 3
H.R. 9096 - Pharmacists Fight Back Act

Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation


17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP)

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
JC
Scott
​
​
Jonathan
Heafitz
​
​
Jocelyn
Wiles
​
​
Lucia
Lebens
​
​
Emily
Threadgill
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address
​
City
​
State
​
Zip Code
​
Country
​

21. Client new principal place of business (if different than line 20)

City
​
State
​
Zip Code
​
Country
​

22. New General description of client’s business or activities

​

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name
Last Name
Suffix
First Name
Last Name
Suffix
1
​
​
​
3
​
​
​
2
​
​
​
4
​
​
​

ISSUE UPDATE

24. General lobbying issue that no longer pertains

​
​
​
​
​
​
​
​
​

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

Name Address Principal Place of Business
(city and state or country)
Street Address
City State/Province Zip Country
City
State Country

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

1 2 3

FOREIGN ENTITIES

27. Add the following foreign entities:

Name Address Principal place of business
(city and state or country) 		Amount of contribution for lobbying activities Ownership percentage in client
Street Address
City State/Province Country
City
State Country
%

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

1 3 5
2 4 6

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

Lobbyist Name Description of Offense(s)